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Although	 developments	 in	 radiation	 therapy	 techniques	
have	 improved	outcomes	 for	patients	with	clinically	 localized	
prostate	 cancer,	 relapse	 remains	 an	 issue	 despite	 the	 addition	
of	hormonal	 therapy	(1).	Although	treatment	failure	following	
radiation	 therapy	depends	on	various	parameters,	 the	hypoxic	
microenvironment	 of	 the	 tumor	 can	 also	 provide	 an	 explana-
tion.	In	clinically	localized	prostate	cancer,	tumor	hypoxia	has	
been	linked	to	higher	biochemical	failure	(BF)	rates	and	poorer	
prognosis	(2).	Hypoxia	and	angiogenesis	are	important	factors	
in	tumorigenesis	and	the	response	to	cancer	treatment.	Vascular	
endothelial	growth	factor	(VEGF)	is	a	key	molecule	in	angio-
genesis	that	has	a	major	role	in	cancer	growth.	High	VEGF	ex-
pression	is	the	result	of	adaptation	to	low	oxygenation	(hypoxia)	
in	the	microenvironment	of	tumor	(3,	4).
The	principal	antitumor	mechanism	of	antiangiogenic	agents	
is	through	the	inhibition	of	endothelial	cell	function,	an	event	
that	leads	to	a	reduction	in	tumor	blood	flow,	tumor	hypoxia,	
and	 cell	 death.	 The	 use	 of	 novel	 targeted	 therapies,	 such	 as	 
anti-VEGF	agents,	in	addition	to	standard	therapies	is	a	promis-
ing	approach	to	increase	the	efficacy	of	treatment	for	resistant	
disease.	Studies	have	shown	that	anti-VEGF	agents	can	enhance	
radiation-induced	inhibition	of	tumor	growth	(5,	6).	Increased	
VEGF	expression	has	predicted	a	shorter	time	to	BF	following	
definitive	radiation	therapy,	regardless	of	clinical	stage,	Glea-
son	score,	prostate	specific	antigen	(PSA)	level,	and	radiation	
dose	(7).	The	aim	of	the	present	study	was	to	correlate	VEGF	
expression	with	 outcome	 in	 patients	with	 clinically	 localized	
prostate	cancer	treated	with	radiation	therapy.
MATERIAL AND METHODS
Patient population
Between	1997	and	2006,	264	patients	with	prostate	cancer	were	
treated	with	 radiation	 therapy	 at	 the	Department	 of	Radiation	On-
Background:	Anti-vascular	endothelial	growth	factor	(Anti-VEGF)	
agents	are	a	promising	approach	to	increase	the	efficacy	of	treatment	
for	treatment-resistant	prostate	cancer.
Aims:	To	correlate	vascular	endothelial	growth	 factor	 (VEGF)	ex-
pression	and	outcome	following	radiation	therapy	in	the	treatment	of	
clinically	localized	prostate	cancer.
Study Design:	Retrospective	observational	study.
Methods:	 Forty-one	 patients	 and	 clinically	 localized	 disease	 that	
were	 treated	with	 radiation	 therapy	were	 analyzed.	For	VEGF	ex-
pression,	immunoreactivity	scores	(IRS)	were	calculated	using	per-
cent	scores	and	intensity	scores.	Twenty-four	patients	were	classified	
as	having	low	(0	to	4	IRS)	and	17	patients	were	classified	as	having	
high	(5	to	8	IRS)	VEGF	expression.
Results:	The	median	age	was	71	years,	median	follow-up	was	5.4	
years	and	median	radiation	therapy	dose	was	70	Gy.	VEGF	expres-
sion	was	 calculated	 as	 low	 in	 24	 patients	 and	 high	 in	 17	 patients.	
Higher	 VEGF	 expression	 was	 observed	 in	 6/26	 patients	 with	 a	
low	Gleason	score	versus	11/15	patients	with	a	high	Gleason	score	
(p=0.02).	 Biochemical	 failure	 (BF)	 was	 observed	 in	 2/24	 patients	
with	 low	VEGF	 expression	 versus	 7/17	 patients	 with	 high	VEGF	
expression	 (p=0.01).	 In	 univariate	 analysis,	 having	 a	 higher	Glea-
son	score	(p<0.01),	being	in	the	high	risk	group	(p=0.03)	and	having	
higher	VEGF	expression	 (p=0.01)	predicted	BF	after	definitive	 ra-
diation	therapy.	The	biochemical	failure-free	survival	rate	at	5	years	
tended	 to	be	different	 (91%	vs.	53%)	when	patients	were	grouped	
according	to	VEGF	expression	(p=0.06).
Conclusion:	 In	 attempt	 to	 define	patients	with	 clinically	 localized	
disease	 that	are	not	sensitive	 to	standard	 treatment	modalities,	cel-
lular	and/or	molecular	biological	markers	may	be	required.
(Balkan Med J		2014;31:43-49).
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cology,	 Gazi	 University	 Faculty	 of	Medicine.	 Those	 patients	 who	
did	not	have	clinically	localized	disease,	who	had	undergone	radical	
prostatectomy	 prior	 to	 radiation	 therapy,	who	 had	 received	 a	 total	
dose	<66	Gy,	who	had	been	treated	with	palliative	intent	or	who	had	
diagnostic	biopsies	performed	at	other	institutions	were	excluded.	As	
a	consequence,	41	patients	who	had	received	radiation	therapy	(with	
or	without	hormonal	therapy)	with	curative	intent	for	clinically	local-
ized	disease	were	included	in	this	study.	Oral	informed	consent	was	
obtained	 from	 patients	who	 participated	 in	 this	 study.	All	 patients	
had	adenocarcinomas.	Their	medical	records	were	reviewed	to	assess	
disease	and	treatment	characteristics	and	the	presence	or	absence	of	
BF.	The	end	of	the	follow-up	period	was	March	2009.
Clinical	T	stage	was	T1c	to	T2a	in	22	patients	(54%)	and	≥T2b	in	
19	patients	(46%).	At	the	time	of	diagnosis,	the	mean	PSA	level	was	
17.9	ng/mL	(2-66	ng/mL)	and	the	PSA	levels	of	21	patients	(51%)	
were	≤10	ng/mL.	Gleason	scores	reported	from	transrectal	biopsies	
were	≤6	in	26	patients	(63%)	and	>6	in	15	patients	(37%)	(Table	1).	
According	to	the	risk	classification	scheme	proposed	by	D’Amico	et	
al.	(8),	18	patients	(44%)	were	classified	into	the	low-risk	group,	eight	
patients	(19.5%)	were	classified	into	the	intermediate-risk	group	and	
15	patients	(36.5%)	were	classified	into	the	high-risk	group.	
Treatment technique
All	patients	were	treated	with	high	energy	linear	accelerators	(10	
MV	and/or	15	MV	photon	beams)	(Saturn	41,	General	Electric,	Buc,	
France).	Patients	were	generally	treated	with	the	four-field	box	tech-
nique.	Planning	treatment	volume	was	the	prostate	and	the	vesicles	
with	 margins.	 Regional	 nodes	 were	 prophylactically	 included	 for	
high	risk	patients	(with	PSA	>20	ng/mL	and/or	Gleason	score	>7).	
The	majority	of	patients	were	treated	to	70	Gy	with	daily	fractions	of	
2	Gy.	Ten	patients	(24%)	were	treated	with	radiation	therapy	alone	
while	31	patients	 (76%)	received	either	short-term	(17	patients)	or	
long-term	(14	patients)	hormonal	therapy	(Table	1).	All	patients	had	
PSA	testing	at	regular	three-monthly	intervals	during	follow-up.
Assessment of VEGF expression
Tissue	sections	of	4	μm	were	cut	from	previously	prepared	rep-
resentative	 formalin-fixed	 and	 paraffin-embedded	 blocks.	 Sections	
were	 deparaffinized	 in	 xylene	 and	 rehydrated.	 Immunoperoxidase	
staining	 was	 performed	 using	 the	 streptavidin-biotin	 peroxidase	
method.	The	sections	were	treated	with	0.3%	H
2
O
2
	in	order	to	sup-
press	endogenous	peroxidase	activity.	Sections	were	pretreated	with	
ethylenediaminetetraacetic	acid	(EDTA)	to	retrieve	antigen	expres-
sion	and	incubated	with	anti-VEGF	monoclonal	antibody	(1:50	dilut-
ed,	clone	VG1,	NeoMarkers).	As	a	chromogen	for	color	development,	
3-amino-9-ethylcarbazole	substrate	(AEC;	LabVision,	NeoMarkers)	
was	used.	The	slides	were	counterstained	with	hematoxylin,	dehy-
drated	 and	 mounted.	 Sections	 of	 angiosarcoma	 were	 used	 as	 the	
positive	control.	For	the	negative	control,	phosphate	buffered	saline	
replaced	the	primary	antibody.	Stained	slides	were	examined	to	iden-
tify	VEGF	immunoreactivity.	VEGF	expression	was	assessed	using	a	
semiquantitative	scoring	method	that	was	blinded	to	patient	outcome.	
The	percentage	of	positively	stained	glands	(none=0;	less	than	1%=1,	
1-10%=2;	11-33%=3;	34	 -67%=4;	and	more	 than	67%=5)	and	 the	
staining	intensity	(none=	0;	weak=	1;	moderate=	2;	strong=	3)	were	
evaluated.	The	percentage	scores	and	the	intensity	scores	were	added	
to	give	a	final	immunoreactivity	score	(IRS)	that	ranged	from	0	to	8.	
For	the	purpose	of	statistical	analysis,	IRS	was	classified	as	low	(0	to	
4)	or	high	(5	to	8)	(9).
Statistical analysis
For	the	purpose	of	statistical	analysis	(due	to	the	limited	number	
of	patients),	the	intermediate-risk	group	and	the	high-risk	group	were	
merged	to	define	low-risk	patients	(clinical	T	stage	T1c	to	T2a,	initial	
PSA	≤10	ng/mL	and	Gleason	score	≤6)	and	high-risk	patients	(clinical	
T	stage	≥T2b	and/or	initial	PSA	>10	ng/mL	and/or	Gleason	score	≥7).	
BF	was	defined	as	rising	PSA	levels	in	three	consecutive	measure-
ments	following	radiation	therapy.	Overall	survival	(OS)	was	calcu-
lated	from	the	final	day	of	radiation	therapy	to	death.	Patients	who	
were	alive	were	censored	at	their	last	follow-up	for	OS.	Biochemical	
failure-free	survival	(BFFS)	was	calculated	from	the	final	day	of	ra-
diation	therapy	to	the	time	when	BF	was	established.	Patients	dying	
without	BF	were	classified	as	censored	observations	at	 the	 time	of	
death	and	all	other	patients	were	censored	at	their	last	follow-up	for	
the	BFFS.	
Statistical	analysis	was	performed	using	SPSS	for	Windows	ver-
sion	17.0	(SPSS	Inc.,	2008,	Chicago,	IL,	USA).	Differences	between	
patient	groups	were	evaluated	using	the	chi-square	test.	Survival	es-
timations	were	 performed	using	 the	method	of	Kaplan	 and	Meier,	
univariate	analysis	using	the	log-rank	test	and	log-rank	test	for	linear	
trend.	Statistical	significance	was	considered	when	the	p-value	was	
less	than	or	equal	to	0.05.
RESULTS
The	median	age	was	71	years	(range,	58-82	years).	The	me-
dian	radiation	therapy	dose	was	70	Gy,	ranging	from	66	to	74	
Gy.	Follow-up	ranged	from	3	to	12.2	years	(median,	5.4	years).
VEGF expression
VEGF	expression	was	evaluated	as	low	in	24	patients	(59%)	
and	high	in	17	patients	(41%)	(Table	1).	Higher	VEGF	expres-
sion	was	observed	in	16	out	of	22	patients	with	a	low	clinical	T	
stage	as	compared	to	in	8	out	of	19	patients	with	a	high	clini-
cal	T	stage,	the	difference	being	statistically	significant	(p=0.05,	
χ2=3.94).	VEGF	was	overexpressed	in	7	out	of	21	patients	with	
a	low	initial	PSA	level	as	compared	to	10	out	of	20	patients	with	
a	high	initial	PSA	level;	this	difference	was	not	statistically	sig-
nificant	 (p>0.05,	 χ2=1.17).	On	 the	 contrary,	 higher	VEGF	ex-
pression	was	observed	in	6	out	of	26	patients	with	a	low	Glea-
son	score	as	compared	to	in	11	out	of	15	patients	with	a	high	 
Gleason	 score;	 this	 difference	 was	 statistically	 significant	
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(p=0.02,	χ2=9.89).	However,	when	defined	risk	groups	based	on	
the	initial	PSA	level	and	Gleason	score	were	analyzed,	VEGF	
was	overexpressed	in	4	out	of	18	patients	in	the	low	risk	group	as	
compared	to	in	13	out	of	23	patients	in	the	high	risk	group;	this	
difference	was	statistically	significant	(p=0.03,	χ2=4.89).
Biochemical failure
For	the	entire	group,	BF	was	observed	in	9	patients	(22%).	
BF	was	observed	in	none	of	the	22	patients	with	a	low	clinical	T	
stage	as	compared	to	in	9	out	of	19	patients	with	a	high	clinical	
T	stage;	this	difference	was	statistically	significant	(p<0.001,	
χ2=13.35).	BF	was	observed	in	3	out	of	21	patients	with	a	low	
initial	PSA	level	as	compared	to	6	out	of	20	patients	with	a	
high	initial	PSA	level;	this	difference	was	not	statistically	sig-
nificant	(p>0.05,	χ2=1.48).	On	the	contrary,	BF	was	observed	
in	1	out	of	26	patients	with	a	low	Gleason	score	as	compared	
to	in	8	out	of	15	patients	with	a	high	Gleason	score;	this	differ-
ence	was	 statistically	 significant	 (p<0.001,	 χ2=13.59).	How-
ever,	when	defined	risk	groups	based	on	the	initial	PSA	level	
and	Gleason	score	were	analyzed,	BF	was	reported	in	none	of	
the	18	patients	in	the	low	risk	group	as	compared	to	in	9	out	of	
23	patients	in	the	high	risk	group;	this	difference	was	statisti-
cally	significant	(p=0.03,	χ2=9.02).	BF	was	observed	in	2	out	
of	24	patients	with	low	VEGF	expression	as	compared	to	in	7	
out	of	17	patients	with	high	VEGF	expression;	this	difference	
was	statistically	significant	(p=0.01,	χ2=6.27).
In	the	univariate	analysis,	having	a	higher	clinical	T	stage	
(p<0.001),	having	a	higher	Gleason	score	(p<0.01),	being	in	
the	high	risk	group	(p=0.03)	and	having	higher	VEGF	expres-
sion	(p=0.01)	were	predictors	of	BF	after	definitive	radiation	
therapy	(Table	2).
Biochemical failure free survival
The	biochemical	failure	free	survival	(BFFS)	rate	at	5	years	
was	76%	for	the	entire	group	of	patients.	The	BFFS	rate	at	5	
years	was	100%	vs.	46%	when	patients	were	grouped	accord-
ing	to	clinical	T	stage	(p<0.001),	86%	vs.	63%	when	patients	
were	 grouped	 according	 to	 the	 initial	 PSA	 level	 (p=0.17),	
96%	vs.	 42%	when	patients	were	 grouped	 according	 to	 the	 
Gleason	 score	 (p<0.01)	 and	 100%	 vs.	 54%	 when	 patients	 
were	grouped	according	to	risk	groups	(p=0.001).	The	BFFS	
rate	at	5	years	tended	to	be	different	(91%	vs.	53%)	when	pa-
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	 	 	 BF	 	 																																							BFFS	at	5	years
	 	 N	(%)	 p-value	 χ2	 %	(n)	 p-value
Clinical	T	stage
	 T1c	and	T2a	 0	(0)	 <0.001	 13.35	 100±0	(n=22)	 <0.001
	 ≥T2b	 9	(47)	 	 	 46±13	(n=4)	
Initial	PSA	level
	 Low	(≤10	ng/mL)	 3	(14)	 >0.05	 1.48	 86±8	(n=8)	 0.17
	 High	(>10	ng/mL)	 6	(30)	 	 	 63±12	(n=6)	
Gleason	score
	 Low	(<7)	 1	(4)	 <0.001	 13.59	 96±4	(n=11)	 <0.01
	 High	(≥7)	 8	(53)	 	 	 42±14	(n=3)	
Risk	Group
	 Low-risk	patients	 0	(0)	 0.03	 9.02	 100±0	(n=18)	 0.001
	 High-risk	patients	 9	(39)	 	 	 54±11	(n=6)	
VEGF	expression
	 Low	(0-4)	 2	(8)	 0.01	 6.27	 91±6	(n=9)	 0.06
	 High	(5-8)	 7	(41)	 	 	 53±13	(n=5)	
BF:	biochemical	failure;	BFFS:	biochemical	failure-free	survival;	N:	number	of	patients;	n:	number	of	remaining	patients;	PSA:	prostate	specific	antigen;	VEGF:	vascular	endot-
helial	growth	factor
TABLE 2.	Biochemical	failure	(BF)	and	biochemical	failure-free	survival	(BFFS)	at	5	years	by	patient	characteristics
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	 	 N	(%)
Age
	 <71	years	 20	(49)
	 ≥71	years	 21	(51)
Clinical	T	stage
	 T1c	and	T2a	 22	(54)
	 ≥T2b	 19	(46)
Initial	PSA	level
	 Low	(≤10	ng/mL)	 21	(51)
	 High	(>10	ng/mL)	 20	(49)
Gleason	score
	 Low	(<7)	 26	(63)
	 High	(≥7)	 15	(37)
Risk	group
	 Low-risk	patients	 18	(44)
	 High-risk	patients	 23	(56)
VEGF	expression
	 Low	(0-4)	 24	(59)
	 High	(5-8)	 17	(41)
N:	number	of	patients;	PSA:	prostate	specific	antigen;	VEGF:	vascular	endothelial	
growth	factor
TABLE 1.	Patient	characteristics
tients	were	grouped	according	to	VEGF	expression	(p=0.06)	
(Table	2,	Figure	1	a-e).
DISCUSSION
Radiation	therapy	(with	or	without	hormonal	therapy)	is	the	
primary	 treatment	option	 for	 patients	with	 clinically	 localized	
prostate	cancer.	Well-documented	prognostic	factors	such	as	T-
stage,	Gleason	score	and	PSA	indicate	the	natural	history	of	the	
disease	and	determine	the	recurrence	risk	(10,	11).	However,	it	
might	be	challenging	to	identify	patients	who	are	at	 increased	
risk	 for	 recurrence.	Therefore,	 cellular	 and	molecular	biologi-
cal	markers	that	might	better	predict	possible	radiation	therapy	
resistance	and	outcome	are	needed	to	make	treatment	decisions.
Folkman	(12)	showed	that	angiogenesis	is	a	necessary	com-
ponent	of	solid	tumor	growth.	VEGF	is	a	key	regulator	of	an-
giogenesis	and	is	involved	in	tumor	angiogenesis	by	increasing	
vascular	 permeability,	 endothelial	 cell	 growth,	 proliferation,	
migration	and	differentiation	(13).	VEGF	overexpression	takes	
place	through	the	adaptation	of	the	tumor	microenvironment	to	
hypoxia	(14).	Tumor	hypoxia	might	be	an	explanation	for	treat-
ment	failure	following	radiation	therapy.	Hypoxia	has	been	as-
sociated	with	poor	prognosis	in	a	variety	of	cancers	including	the	
stomach,	the	esophagus,	the	breast,	the	colorectum,	the	head	and	
neck	and	the	cervix	(15-20,	3,	4).
Some	studies	have	reported	a	relationship	between	VEGF	
expression	and	poorer	tumor	control	together	with	diminished	
survival	following	radiation	therapy	in	different	cancers	such	
as	the	rectum,	the	breast	and	the	cervix.	Peng	et	al.	(21)	report-
ed	that	VEGF	expression	may	predict	distant	metastases	and	
disease-free	survival	in	stage	III	rectal	cancer	following	pre-
operative	radiation	therapy	and	also	suggested	that	inhibition	
of	VEGF	in	combination	with	radiation	therapy	may	improve	
outcome.	Linderholm	et	al.	(18)	showed	that	high	VEGF	ex-
pression	can	point	to	a	resistant	phenotype	for	node-negative	
breast	cancer	patients	treated	with	only	locoregional	radiation	
therapy,	or	indicate	early	metastases	which	requires	treatment.	
Another	study	evaluating	the	relationship	between	VEGF	ex-
pression	and	radiation	therapy	outcome	in	advanced	cervical	
cancer	reported	that	expression	of	VEGF,	as	assessed	by	IHC	
analysis,	is	a	highly	significant	prognostic	factor	for	survival	
and	metastasis-free	survival	but	not	for	local	control	(22).
For	 clinically	 localized	 prostate	 cancer,	 the	 role	 of	 tu-
mor	hypoxia	 and	 angiogenesis	 has	 recently	 come	under	 the	
spotlight.	The	presence	of	hypoxic	regions	in	prostate	cancer	
has	been	documented	 in	 the	 literature,	both	 through	 the	use	
of	 physical	measurements	 (such	 as	 the	pO
2
	probes)	 and	 the	
identification	of	specific	biomarkers.	In	their	study	on	patients	
with	localized	prostate	cancer,	Movsas	et	al.	(2)	reported	that	
tumor	hypoxia	was	associated	with	poor	prognosis,	since	low	
pO
2
	levels	(measured	by	an	Eppendorf	microelectrode)	in	the	
prostate	 were	 associated	 with	 higher	 BF	 assessed	 by	 PSA.	
Furthermore,	Cvetkovic	et	al.	 (9)	demonstrated	a	significant	
correlation	between	preoperative	prostate	hypoxia	 level	 (as-
sessed	by	an	Eppendorf	oxygen	microelectrode)	and	the	per-
centage	of	cells	staining	positive	for	VEGF.	One	of	the	earliest	
VEGF	expression	 studies	 showed	 that	 the	majority	of	pros-
tatic	carcinoma	specimens	exhibited	cytoplasmic	staining	for	
VEGF,	with	VEGF	expression	increasing	with	dedifferentia-
tion	of	the	tumor	(23).	Peyromaure	et	al.	(24)	studied	VEGF-
A	 expression	 in	 prostate	 cancer	 patients	 undergoing	 radical	
prostatectomy.	They	found	higher	expression	of	VEGF	in	men	
who	developed	bone	metastases	as	compared	to	those	who	re-
mained	free	of	recurrence	following	surgery.	As	a	result,	they	
suggested	that	VEGF	expression	could	be	a	factor	associated	
with	cancer	progression	following	radical	prostatectomy.
In	 the	 present	 study,	 higher	 VEGF	 expression	 was	 ob-
served	in	27%	of	patients	with	a	low	clinical	T	stage	as	com-
pared	to	58%	of	patients	with	a	high	clinical	T	stage.	VEGF	
was	overexpressed	in	33%	of	patients	with	a	low	initial	PSA	
level	as	compared	to	50%	of	patients	with	a	high	initial	PSA	
level.	On	the	contrary,	higher	VEGF	expression	was	observed	
in	23%	of	patients	with	a	low	Gleason	score	as	compared	to	
73%	of	patients	with	a	high	Gleason	score.	Furthermore,	BF	
was	observed	in	8%	of	patients	with	a	low	VEGF	expression	
as	compared	to	of	41%	of	patients	with	a	high	VEGF	expres-
sion.	The	BFFS	rate	at	5	years	was	91%	for	patients	with	a	low	
VEGF	expression	versus	53%	for	patients	with	a	high	VEGF	
expression.	There	have	only	been	a	few	studies	that	differenti-
ated	patients	with	radiation	therapy	sensitive	prostate	cancer	
from	 those	with	 a	 poor	 outcome.	 In	 agreement	with	 the	 re-
sults	of	our	study,	Green	et	al.	(25)	reported	that	higher	tumor	
VEGF	 expression	 on	 pretreatment	 biopsies	 was	 correlated	
with	 an	 adverse	 outcome	 following	 radiation	 therapy.	They	
found	 that	VEGF	was	 the	only	 significant	prognostic	 factor	
in	 terms	 of	 disease-specific	 survival	 (p=0.035).	 They	 also	
reported	 a	 statistically	 significant	 association	 between	 high	
VEGF	expression	and	increased	Gleason	score	(p=0.02),	but	
failed	 to	observe	any	correlation	between	VEGF	expression	
and	BF,	in	contrast	with	the	results	of	our	study.	Vergis	et	al.	
(7)	evaluated	 intrinsic	markers	of	hypoxia	and	angiogenesis	
(HIF-1α,	osteopontin	and	VEGF)	in	relation	to	the	outcome	
of	 localized	 prostate	 cancer	 patients	who	were	 treated	with	
curative	intent,	either	using	radical	radiation	therapy	or	radi-
cal	prostatectomy.	They	reported	that	increased	expression	of	
VEGF	was	a	significant	predictor	of	worse	freedom	from	BF	
for	patients	 treated	with	 radical	 radiation	 therapy	as	well	as	
those	 treated	with	 radical	 prostatectomy,	 in	 agreement	with	
the	results	of	our	study.
In an attempt	 to	 define	 patients	 with	 clinically	 localized	
prostate	cancer	who	are	sensitive	to	standard	treatment	modali-
ties	such	as	surgery,	radiation	therapy	and	hormonal	therapy,	
it	is	clear	that	cellular	and/or	molecular	biological	markers	are	
Balkan Med J, Vol. 31, No. 1, 2014
46 Erkal	et	al.	Vascular	Endothelial	Growth	Factor	in	Prostate	Cancer
Balkan Med J, Vol. 31, No. 1, 2014
47Erkal	et	al.	Vascular	Endothelial	Growth	Factor	in	Prostate	Cancer
FIG. 1. a-e. Biochemical failure-free survival compared according to clinical T stage (a). Biochemical failure-free survival compared according to initial PSA 
level (b). Biochemical failure-free survival compared according to Gleason score (c). Biochemical failure-free survival compared according to risk groups 
(d). Biochemical failure-free survival compared according to VEGF expression (e)
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required.	The	relationship	between	VEGF	and	prostate	cancer	
has	been	extensively	studied.	However,	only	a	small	number	of	
studies	evaluated	the	effects	of	VEGF	expression	on	outcome,	
regardless	of	the	treatment	modality	used.	Furthermore,	these	
studies	were	underpowered	in	terms	of	both	the	number	of	pa-
tients	 involved	 and	 the	 extent	 of	 follow-up.	Vergis	 et	 al.	 (7)	
speculated	that	the	associations	between	clinical	outcome	and	
staining	for	VEGF	(as	well	as	other	markers	of	hypoxia	such	
as	HIF-1α	and	osteopontin)	are	not	sufficient	to	conclude	that	
tumor	 hypoxia	 and	 angiogenesis	 adversely	 affect	 treatment	
efficacy	and	that	these	markers	constitute	therapeutic	targets.	
Furthermore,	they	suggested	that	“VEGF	might	only	serve	as	
one	of	 the	markers	pointing	 to	an	aggressive	 tumor	 type”.	 It	
is	for	the	aggressive	counterparts	of	prostate	cancer	that	anti-
VEGF	 treatments	 could	 prove	 beneficial.	 Recent	 preclinical	
studies	have	shown	that	anti-VEGF	agents	can	“normalize”	tu-
mor	associated	blood	vessels,	which	is	a	mechanism	of	radio-
sensitization	(26,	27).	Based	on	the	results	of	these	preclinical	
studies,	Vuky	et	al.	(28)	designed	a	phase	II	study	examining	
the	effect	of	an	anti-VEGF	agent	concurrently	with	radiation	
therapy	for	high	risk	prostate	cancer.	They	reported	that	the	an-
ti-VEGF	agent	did	not	appear	to	exacerbate	the	acute	effects	of	
radiation	therapy;	however,	the	impact	on	outcome	remained	
unclear.	Therefore,	as	a	conclusion,	further	investigations	that	
aimed	to	associate	VEGF	as	well	as	other	markers	of	angio-
genesis	and	hypoxia	with	treatment	outcome	are	required	for	
patients	with	clinically	localized	prostate	cancer.	
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